Aller au contenu principal
Accès ouvert déclaré 2026 article

Engineering a T7 bacteriophage to attenuate LPS-driven inflammatory responses during bacteriolysis

2Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

ABSTRACT Bacterial lysis during treatment of Gram-negative infections can release lipopolysaccharide (LPS) and aggravate inflammation. Here, we engineered two complementary T7 bacteriophages: T7- nluc , a NanoLuc reporter bacteriophage for real-time monitoring of viable bacteria, and T7- phoa , a therapeutic bacteriophage that releases alkaline phosphatase (PhoA) during lysis to reduce LPS bioactivity. Both engineered bacteriophages retained lytic activity similar to that of wild-type T7. In vitro , T7- nluc produced a low-background bioluminescent signal that reflected bacterial burden, whereas T7- phoa released catalytically active PhoA into the extracellular environment. In Galleria mellonella and Danio rerio infection models, T7- nluc enabled dynamic monitoring of infection progression, while T7- phoa improved survival, reduced inflammatory responses, and accelerated inflammatory resolution without compromising bacterial clearance. These findings support a modular bacteriophage engineering strategy that combines bacterial killing, real-time infection monitoring, and local attenuation of LPS-driven inflammation, offering a potential approach for improving bacteriophage-based treatment of Gram-negative infections. IMPORTANCE Bacteriophage therapy is being reconsidered for treating drug-resistant Gram-negative infections, but there is concern that rapid bacterial lysis may release LPS and worsen inflammation. We used bacteriophage T7 as a platform to test whether bacteriophages can be engineered to both fight bacteria and soften these harmful host responses. First, we created a NanoLuc reporter bacteriophage that produces light only when it grows in live bacteria, confirming that engineered bacteriophages can deliver active proteins directly in infected animals. We then built a therapeutic T7- phoa bacteriophage designed to release enzymatically active alkaline phosphatase upon on-target lysis, thereby providing lysis-coupled local phosphatase activity at the infection site. In both G. mellonella and Danio rerio models, infection-site fluids collected after treatment showed elevated phosphatase activity in the T7- phoa group, and the treatment was associated with lower inflammatory peaks, improved survival, and preserved bacterial clearance. Together, these results support a modular route for bacteriophage-based strategies that couple bacterial killing with real-time reporting and local control of LPS associated inflammation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Engineering a T7 bacteriophage to attenuate LPS-driven inflammatory responses during bacteriolysis
Date Crossref
20/05/2026
Éditeur
American Society for Microbiology
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Bacteriophages and microbial interactionsCancer Research and TreatmentsVibrio bacteria research studies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.